Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

BACKGROUND: To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) or alum (Algel). METHODS: We did a double-blind, multicentre, randomised, con...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Lancet Infect Dis
Main Authors: Ella, Raches, Vadrevu, Krishna Mohan, Jogdand, Harsh, Prasad, Sai, Reddy, Siddharth, Sarangi, Vamshi, Ganneru, Brunda, Sapkal, Gajanan, Yadav, Pragya, Abraham, Priya, Panda, Samiran, Gupta, Nivedita, Reddy, Prabhakar, Verma, Savita, Kumar Rai, Sanjay, Singh, Chandramani, Redkar, Sagar Vivek, Gillurkar, Chandra Sekhar, Kushwaha, Jitendra Singh, Mohapatra, Satyajit, Rao, Venkat, Guleria, Randeep, Ella, Krishna, Bhargava, Balram
Format: Artigo
Jezik:Inglês
Izdano: Elsevier Ltd. 2021
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7825810/
https://ncbi.nlm.nih.gov/pubmed/33485468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(20)30942-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki